Wyeth-Ayerst's Protonix
Executive Summary
Approval of the proton pump inhibitor pantoprazole is expected in the third quarter of 2000, American Home Products Senior VP-Science & Technology Robert Levy, MD, tells the Chase H&Q Healthcare Conference in San Francisco Jan. 11. The product is "approvable" at FDA. The company expects to be able to provide information requested by FDA from data it has already collected. AHP and Warner-Lambert have discussed a co-promotion agreement for Protonix while pursuing a merger, but Warner-Lambert has now decided to pursue merger negotiations with Pfizer (1see related story, p. 24)
You may also be interested in...
Wyeth Prevenar Approval Expected By End of February
Wyeth-Ayerst is expecting approval of its pneumococcal conjugate vaccine Prevenar by the end of February.
Wyeth Prevenar Approval Expected By End of February
Wyeth-Ayerst is expecting approval of its pneumococcal conjugate vaccine Prevenar by the end of February.
Pfizer/Warner-Lambert Merger Talks Begin: AHP Vows To Press On
The merger negotiations between Warner-Lambert and Pfizer are likely to focus on the $1 bil. gap between Pfizer's offer and Warner's current stock market valuation.